Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) reported Q2 EPS of ($0.26), $0.13 worse than the analyst estimate of ($0.13). Revenue for the quarter came in at $32.81 million versus the consensus estimate of $37.7 million.

For earnings history and earnings-related data on Arrowhead Pharmaceuticals Inc. (ARWR) click here.